In surveillance for cervical neoplasia, cytologically atypical cells of undetermined 2 significance (ASCUS) present a significant clinical issue, often dependent on high risk 3 (HR) human papilloma virus (HPV) testing for triage of patients. HPV type 16 now 4 appears as a critical concern in the follow-up of ASCUS patients. 5
INTRODUCTION 1
The human papillomavirus (HPV) is responsible for 95-100% of cervical cancers-2 worldwide the second most prevalent malignant neoplasm among women (15, 18, 25) . The HPV PCR-LA was performed using extracted DNAs according to the 12 manufacturer's instructions. Briefly, DNAs were amplified in a final reaction volume of 13 100 µl with working master mix containing Tris buffer, KCl, dATP, dCTP, dUTP, dGTP, 14 dTTP, AmpliTaq Gold DNA polymerase, uracil-N-glycosylase, MgCl 2, biotinylated HPV 15 specific and β-globin primers. The mixture was incubated in a GeneAmp PCR System 16 9700 for 2 minutes at 50
• C and 9 minutes at 95 For determination of reproducibility of the Inv2 assay, the coefficients of 8 variation (cv's) were established through repeat testing for high to low viral 'loads' in 9 dilution assays, through replicate testing in separate runs, on different days. CaSki and 10 Hela cell DNA, source materials for HPV 16 and HPV 18, respectively, were employed 11 for known viral 'copy' numbers (Advanced Biotechnology, Inc., Columbia, Maryland). 12
Reactions contained HPV 16 (1.2x10 3 -10x10 3 copies in 4 dilutions) or HPV 18 (5x10 3 -13 10x10
3 copies in two dilutions). For HPV types 16 and 18, cv's for FAM FOZ ratios 14 ranged from 6.63 -2.53% and 9.33 -4.72%, respectively (range from low to high viral 15 loads). FAM FOZ ratios were reproduced with good precision. 16
All specimens were screened for the presence of HPV by Inv2 and HC2 and the 17 results considered within the context of ASCUS or Negative cytology studies (Tables 2-18 3). 19 20 ASCUS cytology specimens and HPV typing. A total of 94 extracted specimens 21 previously identified cytologically as ASCUS were screened for HPV by Inv2 and HC2 22 and stratified into four groups (Table 2A) outlined in the Methods section. These specimens were all re-tested, with the same results 3 (3FS). Of these specimens, two were negative and one was positive for HPV 59, by PCR-4 LA. Accordingly, 3FS results were considered diagnostically uninformative, or 5 indeterminate (Table 2A) . Otherwise, samples positive by both HPV typing 6 methodologies (Inv2 and HC2) variously included 7 samples positive for Inv2 probe set 7 A5/6, 7 samples for probe set A7, 18 samples for probe set A9, 2 samples mixed positive 8 for A5/6 and A7, 2 samples for A5/6 and A9, and 3 samples for A7 and A9. Inv2 with one specimen positive for probe set A5/6, one for A7, and three specimens for 9 A9. Inv2 detected the potential presence of HPV type 16 and/or 18 (probe sets A9 and 10 A7) in 11.0% (4/36) of negative cytology specimens. 11
For the negative cytology specimens, five discordant specimens were identified in 12 36 informative specimens (3 of 39 specimens were 3FS, and indeterminate). These 13 included 4 specimens positive by Inv2 and 1 specimen negative by Inv2 but positive by 14 HC2 for HPV (Tables 3A-B) . PCR-LA was performed on 3 of the 5 discordant cytology 15 negative specimens, with detection of HR HPV type 56 in a single specimen which was 16
Inv2 positive (Table 3B ). The concordance rate between Inv2 and HC2 in negative 17 cytology specimens was 86.1% (31/36). Genotyping Test includes specific recognition of individual types within both low and 7 high risk groups, although the test remains unavailable for clinical use at this time. In its 8 present format, PCR-LA would be problematic in application of the test (strip 9 hybridization) for high throughput. 10
In characterizing Inv2, the assay appears simple to perform, is amenable to use 11 with SurePath fixative, may be semi-automated for DNA extraction, and shows good 12 sensitivity and specificity for ASCUS cytology cases. For routine HPV surveillance, the 13 
